Pfizer details phase 3 sleep apnea trial for ex-Metsera obesity drug
The program extends an obesity candidate Pfizer obtained through Metsera into an indication already won by tirzepatide.
PR
By Priya Raman · Science Reporter
Sep 21 20:38 ETSource: Korea Biomedical Review
The wire
- 01Pfizer has laid out the design of a phase 3 trial testing the obesity drug it acquired from Metsera in obstructive sleep apnea.
- 02Sleep apnea is now a competitive incretin indication, so a second entrant would give prescribers and payers an alternative to tirzepatide.
- 03Enrollment timelines, dosing and endpoint details were not detailed in this report, and no efficacy data have been released.
From the source
Read at koreabiomed.comPfizer details phase 3 sleep apnea trial for ex-Metsera obesity drug